Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.

@article{Yamasaki2011MulticenterPI,
  title={Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.},
  author={Makoto Yamasaki and Hiroshi Miyata and Koji Tanaka and Osamu Shiraishi and Masaaki Motoori and Ying Feng Peng and Takushi Yasuda and Masahiko Yano and Hitoshi Shiozaki and Masaki Mori and Yuichiro Doki},
  journal={Oncology},
  year={2011},
  volume={80 5-6},
  pages={307-13}
}
OBJECTIVE Esophageal squamous cell carcinoma (ESCC) is refractory to current therapeutic regimens and more effective therapies are imperative. To this end, we conducted a multicenter phase I/II trial of docetaxel, cisplatin, and fluorouracil (DCF) combination chemotherapy for ESCC. METHODS The study subjects were 46 patients with advanced or recurrent… CONTINUE READING